ARCHIVE
Resources
Principal content
Johnson & Johnson under pressure from partner Basilea as drug makers point fingers over antibiotic approval delays
’David vs. Goliath battle’ with drug giant draining Basilea resources. by Pharmawire
Mepha Pharma will receive first round bids on 23 October
Ludwig Merckle committed to sale, sources say. by Pharmawire
Acorda Therapeutics’ Fampridine-SR likely to receive FDA approval with REMS/black box label
Fampridine-SR is expected to be approved later this month, despite the drug’s increased risk for seizures. by Pharmawire
AstraZeneca’s Brilinta expected to get expedited approval with no major label restrictions
Experts say the potential blockbuster prevents more deaths than Plavix. by Pharmawire
Boehringer Ingelheim likely to have regulatory submission for Pradaxa delayed
Clinicians see need for examinations of clinical data to find explanations for “unexpected” increase in myocardial infarctions. by Pharmawire
Follow-on biologics for multiple sclerosis unlikely in near future
Process will be too difficult to expect any competition to emerge in the space in the near term. by Pharmawire
Rigel’s R788 CV adverse event profile draws comparisons to Merck’s withdrawn Vioxx, experts say
Company says two agents cannot be compared due to different mechanism of action
Erbitux’s marginal clinical benefit in lung cancer could prompt second look from regulators
FDA could view the data submission package in the same light as the recent EMEA rejection. by Pharmawire
Takeda eyes European footprint, expected to shop for small- to mid-size M&A deals
Could have trouble finding suitable targets. by Pharmawire
Sanofi-Aventis could increase ophthalmology footprint with Allergan seen as strong candidate
Lux Biosciences retains investment bank. by Pharmawire



